HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

4-hydroxyquinazoline

Also Known As:

4(3H)-quinazolinone; 4-quinazolinol; 4-quinazolinone; quinazolin-4-one; 4(1H)-Quinazolinone

Networked: 11 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinazolines: 402
      - Quinazolinones: 124
        4-hydroxyquinazoline: 11

Experts

1.	Chen, Juncheng: 1 article (12/2022)
2.	Li, Yang: 1 article (12/2022)
3.	Liu, Jie: 1 article (12/2022)
4.	Liu, Yun: 1 article (12/2022)
5.	Ouyang, Liang: 1 article (12/2022)
6.	Tang, Pan: 1 article (12/2022)
7.	Wang, Yuxi: 1 article (12/2022)
8.	Yang, Chengcan: 1 article (12/2022)
9.	Yang, Gaoxia: 1 article (12/2022)
10.	Zhang, Dan: 1 article (12/2022)

Related Diseases

1.	Neoplasms (Cancer) 07/15/2019 - "In this study, a highly sensitive and simultaneous LC-MS/MS-based bioanalytical method was developed and validated in rat plasma for the estimation of four novel anti-cancer compounds, BIT-15-67 and BNT-11, belonging to the Thiazolidinedione class, and BNUA-108 and BNUA-48, from the quinazolin-4-one class. " 07/15/2019 - "Validation of a sensitive simultaneous LC-MS/MS method for the quantification of novel anti-cancer thiazolidinedione and quinazolin-4-one derivatives in rat plasma and its application in a rat pharmacokinetic study." 07/20/2023 - "The current work presents an extension of our effort to design and synthesize a series of new quinazolin-4-one derivatives based on their established anti-cancer activities as inhibitors of multiple protein kinases. " 05/01/2014 - "The invention described in this review (WO2013030218) relates to compounds based on the quinazolin-4-one scaffold, their process of preparation and applications to inhibit the ubiquitin-specific protease 7 (USP7), a deubiquitinating enzyme (DUB), which is considered a potentially important new drug target for treating cancer and immunological disorders. "
2.	Triple Negative Breast Neoplasms 12/01/2022 - "Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy."
3.	Septic Shock (Toxic Shock Syndrome) 07/01/2004 - "Because PARP-1 knockout mice are resistant to endotoxin-induced shock and inhibitors of the enzyme were reported to have similar beneficial properties, we investigated the effect of 4-hydroxyquinazoline (4-HQN), a potent PARP-1 inhibitor, on the modulation of kinase cascades and the regulation of transcription factors in a rodent septic shock model. "
4.	Shock 07/01/2004 - "Because PARP-1 knockout mice are resistant to endotoxin-induced shock and inhibitors of the enzyme were reported to have similar beneficial properties, we investigated the effect of 4-hydroxyquinazoline (4-HQN), a potent PARP-1 inhibitor, on the modulation of kinase cascades and the regulation of transcription factors in a rodent septic shock model. "
5.	Schizophrenia (Dementia Praecox) 01/19/2023 - "In summary, the observed antipsychotic activity profile of ALX-171 justifies the further development of the group of quinazolin-4-one derivatives in the search for a new drug candidate for schizophrenia treatment."

Related Drugs and Biologics

1.	2,4-thiazolidinedione (thiazolidinedione)
2.	Ubiquitin-Specific Proteases
3.	Antipyretics
4.	Transcription Factors (Transcription Factor)
5.	Antipsychotic Agents (Antipsychotics)
6.	Protein Kinases (Protein Kinase)
7.	Phosphotransferases (Kinase)
8.	Lipopolysaccharides
9.	Histones (Histone)
10.	Enzymes

Related Therapies and Procedures

1.	Therapeutics